MolecuLight Point-of-Care Wound Imaging Devices Awarded Group Purchasing Agreement with AllSpire Health GPO - Seite 2

"We are thrilled to have entered into a supply contract with AllSpire Health GPO," says Anil Amlani, MolecuLight's CEO. "Through the i:X and DX, we hope to enable significant cost-savings and improvements in clinical outcomes. AllSpire's extensive member base can now easily access the MolecuLight wound imaging devices and see the clinical benefits in their wound care practices."

"We are most impressed with the clinical utility that the MolecuLight i:X and DX devices provide to wound care professionals and are pleased to offer the MolecuLight portfolio via our Group Purchasing Agreement to our member hospitals", says James Wallick, Senior Director, Strategic Sourcing at AllSpire Health GPO. "AllSpire is dedicated to sourcing the most innovative products that help to improve clinical decision-making and cost-efficiencies. We believe that the MolecuLight devices are highly innovative and will help to provide such clinical and operational benefits".

In addition to the clinical benefits, MolecuLight procedures performed in the United States can benefit from an available reimbursement pathway including two CPT codes for physician work to perform "fluorescence imaging for bacterial presence, location, and load" procedures and facility payment for Hospital Outpatient Department (HOPD) and Ambulatory Surgical Center (ASC) settings through an Ambulatory Payment Classification (APC) assignment.

1 Caldwell et al. Surg Clin North Am, 2020, 100(4) 2 Le et al. Adv Wound Care, 2021 3 Rahma S. et.al Diabetes Care 2022;45(7):1601–1609 4 Price et al. Diagnostics, 2020

About MolecuLight Corp.

MolecuLight Corp. is the US subsidiary of MolecuLight Inc., a privately-owned medical imaging company that has developed and is commercializing its proprietary fluorescent imaging platform technology in multiple clinical markets. MolecuLight's suite of commercially released devices, including the MolecuLight i:X and DX fluorescence imaging systems and their accessories, provide point-of-care handheld imaging devices for the global wound care market for the real-time detection of wounds containing elevated bacterial burden (when used with clinical signs and symptoms) and for digital wound measurement. The company is also commercializing its unique fluorescence imaging platform technology for other markets with globally relevant unmet needs including food safety, consumer cosmetics and other key industrial markets.